Literature DB >> 14507746

What is the cost of blindness?

C Meads1, C Hyde.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14507746      PMCID： PMC1920795          DOI： 10.1136/bjo.87.10.1201

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  20 in total

1.  Emotional distress in patients with retinal disease.

Authors:  I U Scott; O D Schein; W J Feuer; M F Folstein; K Bandeen-Roche
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

2.  Minimising the impact of visual impairment. Low vision aids are a simple way of alleviating impairment.

Authors:  T H Margrain
Journal:  BMJ       Date:  1999-06-05

Review 3.  Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.

Authors:  C Meads; C Salas; T Roberts; D Moore; A Fry-Smith; C Hyde
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

4.  Visual impairment and eye diseases in elderly institutionalized Australians.

Authors:  M R VanNewkirk; L Weih; C A McCarty; Y L Stanislavsky; J E Keeffe; H R Taylor
Journal:  Ophthalmology       Date:  2000-12       Impact factor: 12.079

5.  The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors:  S Sharma; G C Brown; M M Brown; H Hollands; G K Shah
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

6.  Helping blind and partially sighted people to read: the effectiveness of low vision aids.

Authors:  T H Margrain
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

7.  Diabetic retinopathy in the West of Scotland: its detection and prevalence, and the cost-effectiveness of a proposed screening programme.

Authors:  W S Foulds; A McCuish; T Barrie; F Green; I N Scobie; I M Ghafour; E McClure; J H Barber
Journal:  Health Bull (Edinb)       Date:  1983-11

8.  Loneliness, depression, and social activity after determination of legal blindness.

Authors:  R L Evans
Journal:  Psychol Rep       Date:  1983-04

9.  Development of a shorter version of the geriatric depression scale for visually impaired older patients.

Authors:  I I Galaria; R J Casten; B W Rovner
Journal:  Int Psychogeriatr       Date:  2000-12       Impact factor: 3.878

10.  Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy.

Authors:  R A Greiner
Journal:  Semin Ophthalmol       Date:  2001-12       Impact factor: 1.975
View more
  28 in total

1.  Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.

Authors:  Steven M Kymes; Michael R Plotzke; Michael A Kass; Michael V Boland; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2010-05

2.  Recent trends in visual impairment and blindness in the UK.

Authors:  Florence Bodeau-Livinec; Geraldine Surman; Monique Kaminski; Andrew R Wilkinson; Pierre-Yves Ancel; Jennifer J Kurinczuk
Journal:  Arch Dis Child       Date:  2007-08-03       Impact factor: 3.791

3.  A revolution in Welsh low vision service provision.

Authors:  T H Margrain; B Ryan; J M Wild
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

Review 4.  Economic cost of age-related macular degeneration: a review of recent research.

Authors:  Kathleen M Ke; Usha Chakravarthy; Ciaran O'Neill
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  How much is the cost of visual impairment: caveat emptor.

Authors:  Catherine Meads; Chris Hyde
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  The calculation and use of economic burden data.

Authors:  K D Frick; S M Kymes
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

Review 7.  Giant cell arteritis: a review.

Authors:  Pravin Patil; Niral Karia; Shaifali Jain; Bhaskar Dasgupta
Journal:  Eye Brain       Date:  2013-03-09

8.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

9.  Consequences of amblyopia on education, occupation, and long term vision loss.

Authors:  B Chua; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

10.  Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

Authors:  Francesco Bandello; Albert Augustin; José-Alain Sahel; Hicham Benhaddi; Cristina Negrini; Klaus Hieke; Gilles H Berdeaux
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.